Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Two Sigma Advisers LP decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 95.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 10,700 shares of the biopharmaceutical company's stock after selling 214,800 shares during the period. Two Sigma Advisers LP's holdings in TG Therapeutics were worth $322,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Arizona State Retirement System increased its position in TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after acquiring an additional 364 shares during the period. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after purchasing an additional 463 shares during the period. New York State Teachers Retirement System raised its position in shares of TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after buying an additional 837 shares during the last quarter. Finally, Redwood Investments LLC raised its position in shares of TG Therapeutics by 0.9% during the fourth quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after buying an additional 886 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on TGTX. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Price Performance

Shares of TGTX stock traded down $0.22 during trading hours on Monday, hitting $39.84. The company had a trading volume of 1,566,383 shares, compared to its average volume of 2,969,748. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm's fifty day moving average is $37.21 and its 200 day moving average is $34.69. The firm has a market capitalization of $6.32 billion, a price-to-earnings ratio of -398.36 and a beta of 1.94.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.07) earnings per share. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.